Improving drug delivery using a fortified lipid bilayer platform
A fortified lipid bilayer platform for improved drug packaging and therapeutic delivery
This study is looking at a new way to deliver medications more effectively for people with Alzheimer's disease by using a special fat layer that helps keep the drugs stable and working better, which could lead to better treatment results and fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11082363 on NIH RePORTER |
What this research studies
This research focuses on enhancing the delivery of therapeutic agents through a specialized lipid bilayer platform. By incorporating cholesterol into the lipid bilayer, the study aims to improve the stability and effectiveness of drug packaging, which is crucial for treating conditions like Alzheimer's disease. The approach involves addressing challenges such as premature content leakage and inefficient tissue penetration, which can hinder treatment outcomes. Patients may benefit from improved therapeutic efficacy and reduced side effects as a result of this innovative delivery system.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related dementias who may benefit from enhanced drug delivery methods.
Not a fit: Patients with conditions unrelated to Alzheimer's disease or those who do not require therapeutic interventions may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease and other conditions, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using lipid-based delivery systems for drug therapies, indicating potential success for this approach.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Lu, Jianqin — University of Arizona
- Study coordinator: Lu, Jianqin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.